GlassScriptPhysician profile
Stephanie Horrocks
NPI 1821557414
$12,142.50
in general payments reported to CMS, 2019-2025
64 companies · $3,267 in 2025
The $3,267 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $2,275 · 2023: $2,700 · 2024: $3,261 · 2025: $3,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,427 · Education: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,426.82 |
| Education | $800.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $904.15 | 2021-2025 | |
| Janssen Biotech, INC. | $740.24 | 2021-2025 | Darzalex, Carvykti, Tecvayli |
| Pfizer INC. | $734.63 | 2021-2025 | |
| Incyte Corporation | $614.33 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Seagen INC. | $573.12 | 2021-2025 | Adcetris, Padcev |
| Abbvie INC. | $558.37 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $515.36 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $454.17 | 2021-2025 | Iclusig, Alunbrig, Ninlaro |
| Janssen Pharmaceuticals, INC | $361.21 | 2021-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $344.37 | 2023-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $342.72 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| Lilly USA, LLC | $324.12 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $311.21 | 2022-2025 | Besremi |
| Celgene Corporation | $305.83 | 2022-2025 | Reblozyl, Breyanzi, Pomalyst |
| Alexion Pharmaceuticals, INC. | $297.02 | 2022-2025 | Ultomiris |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $291.58 | 2021-2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $283.47 | 2022-2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $265.35 | 2022-2025 | Enhertu, Datroway |
| Aveo Pharmaceuticals, INC. | $259.47 | 2023-2025 | Fotivda |
| Amgen INC. | $258.28 | 2021-2023 | Prolia, Evenity, Xgeva |
| Merck Sharp & Dohme LLC | $255.89 | 2021-2025 | Keytruda |
| Emd Serono, INC. | $225.68 | 2021-2025 | Bavencio |
| Glaxosmithkline, LLC. | $221.47 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Taiho Oncology, INC. | $217.69 | 2021-2025 | |
| Genentech USA, INC. | $199.98 | 2022-2024 | Columvi, Lunsumio, Polivy |
| Agios Pharmaceuticals, INC. | $194.34 | 2023-2025 | Pyrukynd |
| Genzyme Corporation | $181.65 | 2022-2024 | |
| Eisai INC. | $141.13 | 2021-2025 | |
| Astellas Pharma US INC | $135.03 | 2022-2025 | Padcev, Vyloy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.74 | 2021-2025 | |
| Gilead Sciences, INC. | $118.58 | 2024-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $115.35 | 2023-2024 | Krazati |
| Exelixis INC. | $112.83 | 2022-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $91.56 | 2024-2025 | |
| Eusa Pharma (US) LLC | $89.25 | 2021-2022 | |
| Beone Medicines USA, INC. | $84.71 | 2025 | Tevimbra, Brukinsa |
| Kyowa Kirin, INC. | $72.41 | 2022-2024 | Poteligeo |
| Array Biopharma INC | $70.47 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Syndax Pharmaceuticals, INC. | $53.51 | 2025 | |
| Legend Biotech USA INC. | $51.95 | 2025 | Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $50.64 | 2023-2024 | |
| Kite Pharma, INC. | $43.28 | 2022-2023 | Yescarta |
| Puma Biotechnology, INC. | $39.47 | 2023-2024 | |
| Accord Healthcare, INC. | $39.37 | 2025 | |
| Deciphera Pharmaceuticals INC. | $38.80 | 2021-2023 | Qinlock |
| Genmab U.S., INC. | $34.97 | 2024 | Epkinly |
| Novocure INC. | $33.04 | 2025 | Optune Lua (Novottf-200t) |
| Sobi, INC | $30.56 | 2025 | |
| Stemline Therapeutics INC. | $29.51 | 2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $29.04 | 2025 | Clonoseq |
| Immunogen, INC. | $26.10 | 2024 | Elahere |
| Sumitomo Pharma America, INC. | $24.84 | 2025 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $24.11 | 2025 | Onivyde |
| Acrotech Biopharma INC. | $23.54 | 2021 | |
| Spectrum Pharmaceuticals INC. | $23.17 | 2024 | Rolvedon |
| Caris Mpi, INC. | $21.89 | 2025 | Mi Cancer Seek |
| Helsinn Therapeutics (U.S.), INC. | $19.81 | 2025 | Akynzeo |
| Alnylam Pharmaceuticals INC. | $19.00 | 2025 | Givlaari |
| Blueprint Medicines Corporation | $18.58 | 2022 | |
| Invivyd INC | $17.59 | 2025 | Pemgarda |
| Coherus Oncology, INC. | $15.27 | 2025 | Udenyca, Loqtorzi |
| Recordati_rare_diseases_inc. | $14.66 | 2024 | Sylvant |
| Pharmaand Gmbh | $14.52 | 2025 | Rubraca |
| Tolmar, INC. | $14.52 | 2025 | Rubraca, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Horrocks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.